SCHEMBL720090

SCHEMBL720090

CCOC(=O)CCN(C)C(=O)c1ccc(NC(c2oc3ccc(OCCCS(C)(=O)=O)cc3c2C)C2CCCCC2)cc1.Cc1c(C(Nc2ccc(C(=O)N(C)CCC(=O)O)cc2)C2CCCCC2)oc2ccc(OCCCS(C)(=O)=O)cc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
HSD17B10 Q99714 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
TP53 P04637 1/20 0.33
PDE4A P27815 3/20 0.33
ESR1 P03372 1/20 0.33
PGR P06401 1/20 0.33
CHRM2 P08172 1/20 0.33
HTR1A P08908 1/20 0.33
ADRA2A P08913 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
CHRM1 P11229 1/20 0.33
DRD1 P21728 1/20 0.33
TBXA2R P21731 1/20 0.33
SLC6A2 P23975 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719411 0.98 KDM4E (0.35) KDM4EALDH1A1HPGDTSHRMAPK1
SCHEMBL719108 0.95 NPC1 (0.37) KDM4EALDH1A1HPGDTSHRMAPK1
SCHEMBL716841 0.89 KDM4E (0.37) KDM4EALDH1A1HPGDTSHRMAPK1
SCHEMBL717377 0.88 KDM4E (0.36) KDM4EALDH1A1HPGDTSHRMAPK1
SCHEMBL721358 0.88 MEN1 (0.40) KDM4EALDH1A1HPGDTSHRMAPK1
SCHEMBL720695 0.88 KDM4E (0.36) KDM4EALDH1A1HPGDTSHRMAPK1
SCHEMBL718844 0.87 KDM4E (0.38) KDM4EALDH1A1HPGDTSHRMAPK1
SCHEMBL721587 0.87 KDM4E (0.35) KDM4EALDH1A1HPGDTSHRMAPK1
SCHEMBL720867 0.87 KMT2A (0.34) KDM4EALDH1A1HPGDTSHRMAPK1
SCHEMBL716683 0.87 NPC1 (0.43) KDM4EALDH1A1TSHRMAPK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP KDM4E 1907/4885ALDH1A1 504/4885HPGD 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.